Charles Schwab Investment Management Inc. Has $5.79 Million Stock Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

Charles Schwab Investment Management Inc. raised its position in Anavex Life Sciences Corp. (NASDAQ:AVXLFree Report) by 2.9% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 622,310 shares of the biotechnology company’s stock after acquiring an additional 17,499 shares during the period. Charles Schwab Investment Management Inc. owned approximately 0.76% of Anavex Life Sciences worth $5,794,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in AVXL. Orion Capital Management LLC acquired a new stake in Anavex Life Sciences in the third quarter valued at approximately $59,000. Dark Forest Capital Management LP bought a new position in shares of Anavex Life Sciences in the third quarter valued at approximately $76,000. Blair William & Co. IL bought a new position in shares of Anavex Life Sciences in the third quarter valued at approximately $80,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Anavex Life Sciences by 351.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,498 shares of the biotechnology company’s stock valued at $88,000 after purchasing an additional 7,395 shares in the last quarter. Finally, Victory Capital Management Inc. bought a new position in shares of Anavex Life Sciences in the fourth quarter valued at approximately $100,000. Institutional investors and hedge funds own 31.55% of the company’s stock.

Insider Buying and Selling

In related news, CEO Christopher U. Missling sold 73,380 shares of the business’s stock in a transaction dated Thursday, March 28th. The stock was sold at an average price of $5.11, for a total transaction of $374,971.80. Following the completion of the transaction, the chief executive officer now directly owns 1,250,210 shares in the company, valued at $6,388,573.10. The transaction was disclosed in a document filed with the SEC, which is available through this link. 11.00% of the stock is owned by company insiders.

Anavex Life Sciences Price Performance

NASDAQ:AVXL opened at $4.06 on Monday. The business has a fifty day simple moving average of $4.17 and a two-hundred day simple moving average of $5.70. Anavex Life Sciences Corp. has a 1 year low of $3.25 and a 1 year high of $10.45. The company has a market capitalization of $343.65 million, a P/E ratio of -8.12 and a beta of 0.66.

Anavex Life Sciences (NASDAQ:AVXLGet Free Report) last announced its quarterly earnings results on Thursday, May 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13). During the same period in the previous year, the firm earned ($0.17) earnings per share. As a group, analysts anticipate that Anavex Life Sciences Corp. will post -0.55 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Anavex Life Sciences in a report on Friday, May 10th.

Read Our Latest Analysis on Anavex Life Sciences

Anavex Life Sciences Company Profile

(Free Report)

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.

Further Reading

Want to see what other hedge funds are holding AVXL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Anavex Life Sciences Corp. (NASDAQ:AVXLFree Report).

Institutional Ownership by Quarter for Anavex Life Sciences (NASDAQ:AVXL)

Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.